Prostate cancer
The Skotheim group is responsible for the ongoing research projects related to this disease in Department of Molecular Oncology. Lothe has contributed to the initiation and development of one of these projects as a co-director for CoE-Cancer Biomedicine, and has co-supervised four PhDs in prostate cancer research with Skotheim as main supervisor.
Long term collaboration (2000 onwards) with Prof Manuel R Teixeira is documented by 34 joint papers, and as external supervisor Lothe have hosted four PhD students from the Portuguese Institute of Oncology.
Selected publications:
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, Axcrona U, Axcrona K, Lothe RA, Skotheim RI. Int J Cancer. 152:945-951, 2023
Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Strømme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, Sveen A, Mathelier A, Lothe RA, Axcrona U, Axcrona K, Skotheim RI. Cancer Gene Ther. 29:1276-1284, 2022
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI. Eur Urol. 75:498-505, 2019
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graça I, Costa-Pinheiro P, Eilertsen IA, Antunes L, Oliveira J, Lothe RA, Henrique R, Jerónimo C. Cancer Lett. 385:150-159, 2017.
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR. Neoplasia. 14:600-11, 2012.
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jerónimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR. Genes Chromosomes Cancer. 51:240-9, 2012
A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Skotheim RI, Thomassen GO, Eken M, Lind GE, Micci F, Ribeiro FR, Cerveira N, Teixeira MR, Heim S, Rognes T, Lothe RA. Mol Cancer. 8:5. 2009
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Ribeiro FR, Henrique R, Hektoen M, Berg M, Jerónimo C, Teixeira MR, Lothe RA. Mol Cancer. 5:33, 2006.
8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Ribeiro FR, Jerónimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR. Clin Cancer Res. 12(13):3961-70, 2006.
Statistical dissection of genetic pathways involved in prostate carcinogenesis. Ribeiro FR, Diep CB, Jerónimo C, Henrique R, Lopes C, Eknaes M, Lingjaerde OC, Lothe RA, Teixeira MR. Genes Chromosomes Cancer. 45(2):154-63, 2006.
The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Henrique R, Saatcioglu F, Esteller M, Teixeira MR, Lothe RA. Mol Cancer. 4(1):8. 2005
Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Teixeira MR, Ribeiro FR, Eknaes M, Waehre H, Stenwig AE, Giercksky KE, Heim S, Lothe RA. Cancer. 101:1786-93, 2004.
High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy. Teixeira MR, Waehre H, Lothe RA, Stenwig AE, Pandis N, Giercksky KE, Heim S. Genes Chromosomes Cancer. 28:211-9, 2000